<DOC>
	<DOCNO>NCT01431716</DOCNO>
	<brief_summary>This study investigate effect switch Flolan® Epoprostenol Injection ( EFI/ACT-385781A ) pulmonary arterial hypertension patient currently treat Flolan® . For purpose patient treat least 12 month Flolan® switch Flolan® EFI/ACT-385781A followed-up 90 day . During 90 day safety tolerability EFI/ACT-385781A closely monitor treated patient . This 90 follow-up provide clinical evidence safety , tolerability , efficacy treatment satisfaction switch Flolan® EFI/ACT-385781A patient pulmonary arterial hypertension .</brief_summary>
	<brief_title>Epoprostenol Injection ( EFI/ACT-385781A ) - Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>1 . Male female age 18 year 2 . Patients follow type pulmonary arterial hypertension ( PAH ) belonging WHO Group I : Idiopathic ( IPAH ) , Heritable ( HPAH ) , Associated ( APAH ) Connective tissue diseases Drugs toxins 3 . Patients treat Flolan® least 12 month stable dose least 3 month prior enrollment 4 . Patients currently treat concomitant PAH therapy list must treat least 90 day stable dose 30 day prior enrollment : Bosentan , Ambrisentan , Sitaxsentan , Sildenafil , Tadalafil 5 . Women childbearing potential must use reliable method contraception 6 . Signed informed consent prior initiation study mandate procedure 1 . Patients respiratory and/or cardiovascular distress need emergency care 2 . Known suspicion pulmonary venoocclusive disease ( PVOD ) 3 . Current use IV inotropic agent 4 . Current use prostacyclin prostacyclin analog Flolan® 5 . Tachycardia heart rate &gt; 120 beats/min rest 6 . PAH related condition specify inclusion criterion 7 . Known hypersensitivity formulation EFI/ACT385781A excipients , Flolan® excipients 8 . Cerebrovascular event ( e.g. , transient ischemic attack stroke ) within 6 month screen 9 . History myocardial infarction 10 . History leftsided heart disease , include follow : hemodynamically significant aortic mitral valve disease restrictive congestive cardiomyopathy leave ventricular ejection fraction &lt; 40 % multigated radionucleotide angiogram ( MUGA ) , angiography , echocardiography unstable angina pectoris lifethreatening cardiac arrhythmia 11 . Chronic bleeding disorder 12 . Central venous line infection within 90 day prior screen and/or history recur line infection 13 . Women pregnant breastfeed 14 . Participation another clinical trial , except observational , receipt investigational product within 30 day prior randomization 15 . Any known factor disease might interfere treatment compliance , study conduct interpretation result drug alcohol dependence psychiatric disease 16 . Known concomitant lifethreatening disease PAH life expectancy &lt; 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>